Peginterferon-α2b and ribavirin

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 1, 2004, Pages 17-25

  Ahn, Joseph ^a   Flamm, Steven ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

HCV; Interferon; Pegintron; Pegylated interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTACID AGENT; ANTIDEPRESSANT AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BIRTH DEFECT; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; DATA ANALYSIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; FATIGUE; FEVER; FIRST PASS EFFECT; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INJECTION SITE; INSOMNIA; IRRITABILITY; LIVER TRANSPLANTATION; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PREVALENCE; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT INDICATION; UNITED STATES;

EID: 2942557181     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.1.17     Document Type: Review

References (48)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. NEJM 341, 556-562 (1999).
2. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31, 777-782 (2000).
3. Seeff LB, Natural history of chronic hepatitis C. Hepatology 36, S35-S46 (2002).
4. Fattovich G, Giustina G, Degos F, Tremolada F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112, 463-472 (1997).
5. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 36, S3-S20 (2002).
6. Poynard T, Leroy V, Cohard M et al, for the Consensus Interferon Study Group. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24, 778-789 (1996).
7. 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. NEJM 339, 1485-1492 (1998).
8. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426-1432 (1998).
9. 2b as initial treatment for chronic hepatitis C. Hepatology. 34, 395-403 (2001).
10. 2b in patients with chronic hepatitis C. Clin. Pharmacol. Ther. 69, 407-421 (2001).
11. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
12. Luxon B, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 24(9), 1363-1383 (2002).
13. He-X-H, Shaw P-C, Tam S-C. Reducing the immunogenicity and improving in the in vitro activity of trichosanthin by site-directed pegylation. Life Sci. 65, 355-368 (1999).
14. 2b. J. Interferon Cytokine Res. 21, 1103-1115 (2001).
15. PEG-Intron, package insert. Schering Corporation, Kenilworth, NJ, USA (2001).
16. 2a (40 kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind multicentre study examining effect of duration of treatment and RBV dose. J. Hepatol. 36(Suppl 1), 3 (2002).
17. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of Hepatitis C. Hepatology 36, S121-S127 (2002).
18. Copegus®, package insert. Roche Pharmaceuticals, Nutley, NJ, USA (2002).
19. Rebetron®, package insert. Schering Corporation, Kenilworth, NJ, USA (2001).
20. Peters M. Mechanisms of action of interferon. Semin. Liver Dis, 9, 235-239 (1989).
21. Thomas HC, Torok ME, Forton DM et al. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J. Hepatol, 31 (Suppl. 1), 152-159 (1999).
22. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103-107 (1998).
23. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and Their Actions. Ann. Rev. Biochem. 56, 727-777 (1987).
24. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit. Rev. Clin. Lab. Sci, 29, 307-341 (1992).
25. 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther, 68, 556-567 (2000).
26. Dusheiko G, Main J, Thomas H, Reichard O et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol, 25(5), 591-598 (1996).
27. 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. NEJM 339, 1493-1499 (1998).
28. Lau JYN, Tam RC, Liang J, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35(5), 1002-1009 (2002).
29. Patterson JL, Fernandez-Loisson R, Molecular mechanism of action of ribavirin. Rev. Infect. Dis. 12, 1139-1146 (1990).
30. 2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol, 46, 563-570 (1998).
31. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J et al. Monitoring of Viral Levels During Therapy of Hepatitis C. Hepatology 36, S141-S151 (2002).
32. Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon-α. Hepatology 26, 226-231 (1997).
33. 2a. Gastroenterology 120, 1438-1447 (2001).
34. Bekkering FC, Stalgis C, McHutchinson JG et al. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 33, 419-423 (2001).
35. 2b and ribavirin in chronic hepatitis C. Hepatology 32, 647-653 (2000).
36. Shiffman ML, Hofmann CM, Thompson EB et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 26, 780-785 (1997).
37. Lindsay KL, Trepo C, Heintges T et al. Introduction to therapy of hepatitis C. Hepatology 36, S114-S120 (2002).
38. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431-435 (1981).
39. 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303-1313 (2002).
40. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanism, and future directions. J. Clin. Oncol. 18, 2316-2326 (2000).
41. Zdilar D, Franco-Bronson K, Buchler N et al. Hepatitis C, interferon-α and depression. Hepatology 31, 1207-1211 (2000).
42. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-α. Gastroenterology 123, 141-151 (2002).
43. Fried MW, Side effects of therapy of hepatitis C and their management. Hepatology 36, S237-S244 (2002).
44. De Franceschi L, Fattovich G, Turrini F, Ayi K et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatits C virus infection: role of membrane oxidative damage. Hepatology 31, 997-1004 (2000).
45. Dieterich DT, Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J. Infect. Dis, 185(Suppl. 2), S128-S137 (2002).
46. McHutchison JG, Manns M, Patel K et al. for the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in Genotype 1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061-1069 (2002).
47. 2a plus ribavirin for chronic Hepatitis C virus infection. NEJM 347(13), 975-982 (2002).
48. FDA Antiviral Drug Products Advisory Committee Meeting Briefing Package (2002).